analog 9

The term "analog 9" is a non-specific identifier used in various research contexts to refer to a diverse range of experimental compounds, each with distinct chemical structures, mechanisms of action, and therapeutic targets. These compounds are typically small molecules or peptidomimetics under preclinical investigation for a variety of conditions. Examples include a thiazole-thiadiazole derivative for diabetes mellitus, a clofarabine analog for triple-negative breast cancer, a quinazolinone derivative with multi-target anticancer activity (EGFR, VEGFR-2, COX-2 inhibition), a dichloroacetophenone analog targeting PDHK1 for non-small-cell lung cancer, a biaryl carboxamide-based peptidomimetic for obesity (pancreatic lipase inhibitor), an indole-based sulfonamide derivative for Alzheimer's disease (AChE/BuChE inhibitor), a bisindolylmethane thiosemicarbazide as a urease inhibitor, a rexinoid for cancer (RXR agonist), a TarO inhibitor for Staphylococci infections, a 9-bromo noscapine analog for cancer and inflammation (microtubule dynamics modulator), a difluoromethylmenadione analog for schistosomiasis (SmTGR inhibitor), and a bispidinone analog for cervical carcinoma (induces apoptosis). Additionally, "analog 9" refers to the active metabolites of approved drugs: 9-β-arabinofuranosylguanine (active form of Nelarabine) for T-cell acute lymphoblastic leukemia, and 9-(2-phosphonylmethoxyethyl) guanine (PMEG, active form of Rabacfosadine/GS-9219/VDC-1101) for canine lymphoma and multiple myeloma. One instance, 9,11-Dideoxy-9α,11α-methanoepoxy prostaglandin F 2α, is noted as a research tool for inducing vascular contraction.